Press release
Press release

Phost’in Therapeutics joins TechShare 2022, Euronext’s paneuropean Pre-IPO training program

Montpellier, France – March 2022, 9th

Phost’in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, today joins TechShare 2022, the pan-European pre-IPO educational program of Euronext. For the 7th year, Euronext is renewing its annual support program for growing European Tech companies (digital, cleantech and healthcare) aiming to go public.